With Latest RA Deal, Janssen Seeks To Improve Outcomes With Small Molecules
This article was originally published in The Pink Sheet Daily
Janssen gets option to Modern’s small-molecule candidates for rheumatoid arthritis that could address both the inflammatory and bone-damaging effects of the disease. An R&D exec says the compounds could be complementary to, or used in combination with, Remicade and Simponi, or as standalone RA therapies.
You may also be interested in...
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.
Of three accelerated approval drugs that have been ordered withdrawn to date, Pepaxto marks the shortest interval between the FDA drugs center's withdrawal proposal and the agency’s final order, suggesting that FDORA’s expedited withdrawal procedures helped move things along more quickly.